Results 141 to 150 of about 13,549 (163)
Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib
Molecular Pharmaceutics, 2012 Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clinical trials to treat patients with multiple myeloma and other types of cancers.
Wooin Lee, Kyung Bo Kim, Eun Ryoung Jang
exaly +2 more sources
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
New England Journal of Medicine, 2015 Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed ...
Albert Oriol +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches: